local_hospital

Centre for Human Drug Research

Address
lock Available on a paid plan

Neurology and Neurodegenerative Diseases

At the Centre for Human Drug Research in Leiden, a major focus is neurology and neurodegenerative disease, with studies looking at Parkinson’s disease, multiple sclerosis, spinal muscular atrophy, amyotrophic lateral sclerosis, and related movement and nerve disorders. These trials are designed to explore new treatments, understand disease mechanisms, and assess how therapies affect brain and nerve function.

  • Parkinson’s disease and Parkinson’s disease with GBA1 mutations
  • Progressive multiple sclerosis and remyelination
  • Spinal muscular atrophy and spinal/bulbar motor disorders
  • Peripheral nerve and movement-related conditions

The research often combines safety and effectiveness testing with detailed assessments of neurological function, helping advance care for people with complex nervous system conditions.

Psychiatry, Mental Health, and Pain

Another important area is psychiatry and psychology, including major depressive disorder, anxiety disorders, and broader mental health conditions. The site also studies chronic pain, neuropathic pain, and pain control approaches, aiming to improve symptom relief and better understand how new therapies influence mood, perception, and comfort.

  • Major depressive disorder and incomplete response depression
  • Generalized anxiety disorder and related anxiety conditions
  • Chronic pain and neuropathic pain
  • Testing how candidate therapies affect brain activity and pain responses

This work supports the development of better treatments for conditions that can strongly affect daily life and well-being.

Immunology, Inflammation, and Autoimmune Disease

The site conducts research in immune system diseases and autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, and other inflammatory conditions. These trials are focused on evaluating new therapies, measuring immune responses, and improving understanding of how inflammation affects different organs and tissues.

  • Rheumatoid arthritis and systemic lupus erythematosus
  • Autoimmune and inflammatory diseases
  • Immune response studies in healthy participants and patients
  • Testing immunomodulatory and anti-inflammatory treatments

This line of research helps clarify how the immune system behaves in disease and supports the search for more targeted treatment options.

Dermatology, Skin Barrier, and Wound Research

Skin-focused studies at the Centre for Human Drug Research include atopic dermatitis, psoriasis, and wound-related research. The trials examine whether new treatments can improve skin barrier function, reduce inflammation, and support better visualization or healing in clinical settings.

  • Atopic dermatitis and eczema-related conditions
  • Psoriasis and inflammatory skin disease
  • Wound and skin healing studies
  • Evaluating new topical and imaging-based approaches

This work is aimed at improving both symptom control and clinical decision-making for common and often persistent skin disorders.

Cardiovascular, Respiratory, and Metabolic Research

The research portfolio also includes cardiovascular disease, respiratory function, and metabolism. Studies look at conditions such as stroke, opioid-induced respiratory depression, and broader cardiometabolic health, with the goal of understanding physiological responses and evaluating new ways to protect vital body functions.

  • Cardiovascular and metabolic diseases
  • Stroke and vascular-related conditions
  • Respiratory safety and breathing response studies
  • Assessing how new therapies affect circulation and metabolism

These trials help researchers measure how the body responds under controlled conditions and support the development of safer, more effective interventions.

Infectious Disease, Immunology, and Public Health

The site also investigates virus diseases and broader public health questions, including studies on rhinovirus-associated illness and immune challenge responses. This research is intended to test prevention strategies, examine host defense, and improve understanding of how infections and inflammation affect people.

  • Rhinovirus-associated illness and respiratory infection
  • Immune challenge and inflammatory response studies
  • Public health and population-related research
  • Evaluating prevention and immune-modulating approaches

By combining infection-focused and immune-based studies, the centre contributes to better strategies for disease prevention and response.

Specialized Human Physiology and Diagnostic Research

A distinctive part of the research at this laboratory and testing facility involves human physiology, diagnostic techniques, and analytical methods. These studies explore nerve excitability, brain activity, vascular responses, and other measurable biological signals to help refine how new treatments are assessed.

  • Investigative and diagnostic techniques
  • Nerve excitability and brain function testing
  • Vascular and physiological response measurements
  • Improving tools for evaluating treatment effects

This area supports early clinical research by providing precise ways to observe how therapies influence the body and nervous system.

Site Overview

assignment
79
connected trials
corporate_fare
54
sponsors
science
14
IMPs

Activity Indicator

Last 6 months

9
Trials started
-36% vs previous period.
14
Trials started 6–12 months ago
79
Total trials linked
Highly Active
trending_downDeclining-36%
1
2
2
1
2
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 9 therapeutic areas and 11 of 14 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
32
Sponsors (total)
54
Active sponsors
28

Sponsor Network

Top 28 by active trials.

lock +27 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +10 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 271 other sites in The Netherlands

description
Trial volume
79
Outperforms 88% of sites
public
Therapeutic diversity
17areas
Outperforms 85% of sites
groups
Sponsor diversity
54sponsors
Outperforms 93% of sites

Therapeutic Area Benchmark — The Netherlands

Select a therapeutic area to compare against other sites in The Netherlands.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: The Netherlands

Market Share

Country: The Netherlands

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Centre for Human Drug Research

lock Showing 1 of 79 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of a Fentanyl Vaccine in Patients with Opioid-Induced Respiratory DepressionARMR Sciences Inc.Phase I/IIRecruitingFeb 2026

IMP list

lock Showing 1 of 14 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Sodium Chloride2Unknown2025-02-192026-03-27

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.